Atlas Trials

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Clinical trial NCT03164967 · COMPLETED

Trial details

NCT number
NCT03164967
Sponsor
ADMA Biologics, Inc.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Humoral Immune Response
Start date
2016-12-29
Primary completion
2022-08-30
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.